Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Luminex Corporation Stories

2013-11-04 16:28:56

AUSTIN, Texas, Nov. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial and operating results for the third quarter ended September 30, 2013. Highlights include the following: (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) -- Consolidated third quarter revenue of $50.8 million -- Third quarter assay revenue of $16.1 million. Infectious disease sales comprised approximately 64 percent of total assay sales, with genetic...

2013-11-04 16:26:18

DUBLIN, November 4, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/dlxd9r/microspheres) has announced the addition of the "Global Microspheres (Hollow & Solid) Market Report 2013-2018" [http://www.researchandmarkets.com/research/dlxd9r/microspheres ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global microspheres market is witnessing very high growth on account of rising...

2013-10-29 16:25:07

UNVEILING NEW SAMPLE-TO-ANSWER SYSTEM AUSTIN, Texas, Oct. 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will host an investor event in Phoenix, Arizona at the Association for Molecular Pathology Annual Meeting on Wednesday, November 13, 2013 beginning at 5:30 pm Mountain time. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Patrick J. Balthrop, president and chief executive officer, and other members of the executive...

2013-10-15 16:26:00

AUSTIN, Texas, Oct. 15, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the third quarter of 2013 on Monday, November 4, 2013 after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2013 on November 4, 2013, at 5:00 p.m. Eastern time. The...

2013-10-01 12:30:55

DUBLIN, October 1, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/m2xz2z/molecular ) has announced the addition of the "Molecular Diagnostics in Genetic Testing" [http://www.researchandmarkets.com/research/m2xz2z/molecular ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Molecular diagnostics in genetic testing brings advanced analytical techniques to the diagnosis and treatment of...

2013-09-23 16:24:12

New Cytochrome P450 2C19 Assay Helps Physicians Optimize Individual Patient Care AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit. This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene. (Logo:...

2013-08-22 16:24:22

AUSTIN, Texas, Aug. 22, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Morgan Stanley Global Healthcare Conference to be held September 9 -11, 2013 in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 12:55 p.m. Eastern time (11:55 a.m. Central time) on Tuesday, September 10, 2013. The...

2013-08-07 16:27:53

AUSTIN, Texas, Aug. 7, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced a restructuring plan focused on its Assay and Related Products ("ARP") Segment's Newborn Screening Group and its Brisbane, Australia office. The Company anticipates it will reduce its workforce by approximately 5% and close its Brisbane, Australia office. This plan has been put in place to reduce expenses and better align the Company's resources with its focused growth initiatives. As...

2013-07-29 16:25:52

ACHIEVES MILESTONE SELLING 10,000TH MULTIPLEXING ANALYZER AUSTIN, Texas, July 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2013. Financial and operating highlights include the following: Consolidated second quarter revenue was $54.3 million, a 12 percent increase over the second quarter of 2012 Second quarter assay revenue of $21.7 million, a 24 percent increase over the second quarter of 2012...

2013-07-22 16:23:39

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has passed a major milestone by shipping its 10,000th multiplexing instrument. This milestone was achieved by shipping a MAGPIX® instrument to Dr. Kimberle Chapin at the Rhode Island Hospital in Providence, R.I., the largest hospital and only Level I trauma center in the state. This MAGPIX instrument will be used initially for assay validation of Luminex's xTAG® Gastrointestinal...